With growing aging population Chinese anti-senile dementia drug market will continue 20%-30% expansion

21 September 2010

According to statistics, the population aged 60 and above in China reached 167.14 million in 2009, accounting for 12.5% of the total It rose by 7.25 million (0.5%) compared with that in 2008. In 2009, the population aged above 80 in China reached 18.99 million. The GDP per capita of developed countries with a large aging population is usually $5,000-$10,000. Among over 70 countries with large aging populations, 36% have the GDP per capita of over $10,000. By contrast, the GDP per capita of China was less than $4,000 in 2009, which indicates that China has entered the aging society ahead of time.

Senile dementia is a common disease among the elderly. Its incidence rate has risen continuously in China in recent years, and senile dementia patients account for 4%-5% in this group of people, 10% in the group aged above 75, and 20% in the group aged over 85, according to the findings of a report added to the offering of Research and Markets. It suggests that the incidence rate of senile dementia will increase by one-fold if the age of the elderly rises by 10 years.

According to conservative estimates, the number of senile dementia patients (including Alzheimer's disease as well as vascular dementia, mixed dementia and the senile dementia caused by systemic diseases) totaled 6-8 million, of which less than a half can receive effective treatment.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight





More Features in Pharmaceutical